SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

SOSA LIPRANDI, Alvaro et al. Rol del bloqueo aldosterónico en la insuficiencia cardíaca post infarto agudo de miocardio. Insuf. card. [online]. 2012, vol.7, n.2, pp. 61-66. ISSN 1852-3862.

    1. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. Isolation from the adrenals of a new crystalline hormone with specially high effectiveness on mineral metabolism. Experientia 1953; 9: 333-335. [ Links ]

    2. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364. [ Links ]

    3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009; 30: 469-477. [ Links ]

    4. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000; 101: 2981-2988. [ Links ]

    5. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 2009; 81: 474-481. [ Links ]

    6. Beigui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthélémy O, Montalescot G. High plasma aldosterone levels on admission arassociated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114: 2604-2610. [ Links ]

    7. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nichols MG, Richards AM. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J 2008; 20: 2489-2496. [ Links ]

    8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. for the Randomized Aldactone Evaluation Study Investigator. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717. [ Links ]

    9. Zannad F, Alla F, Dousset D, Perez A, Pitt B, on behalf of the RALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 2000; 102: 2700-2706. [ Links ]

    10. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565. [ Links ]

    11. Hunt SA et al. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines 2001 and ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation 2005; 112:e154-e235. [ Links ]

    12. Swedberg K, Cleland J, Dargie H et al. Guías de Práctica Clínica sobre diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida. Rev Esp Cardiol 2005; 58(9):1062-1092. [ Links ]

    13. Barisani JL et al. Consenso de diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Sociedad Argentina de Cardiología. Rev Argent Cardiol 2010; 78(2): 166-181. [ Links ]

    14. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Investigators(EPHESUS) Eplerenona, a selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003; 348:1309-1321. [ Links ]

    15. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425-31. [ Links ]

    16. López de Sá E, Rubio R, Martínez E, López-Sendón J. Lecciones del estudio EPHESUS (Eplerenone Post-AMI Heart Failure Efficacy and Survival Study). Rev Esp Cardiol 2006;6(Supl.B):48-58. [ Links ]

    17. Pitt B. Sudden death in patients with acute myocardial infarction. N Engl J Med 2005; 353: 1294. [ Links ]

    18. O´Keefe JH, Abbuisa H, Pitt B. Eplerenone improves prognosis in post myocardial infarction diabetic patients with heart failure: results from the EPHESUS. Diabetes Obes Metab 2008; 10: 492-497. [ Links ]

    19. Pitt B, Bakris G, Ruilope L, DiCarlo L, Mukherjee R et al Serum Potassium and Clinical Outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118:1643-1650. [ Links ]

    20. Ruilope LM. Safety aspects of aldosterone blocking drugs. Eur H J Supl 2011; 13: B40-B42. [ Links ]